Inventiva (NASDAQ:IVA) Shares Gap Down - Here's Why

Key Points

• Inventiva shares fell at the open, dropping from a prior close of $4.84 to $4.63 before last trading around $4.65.
• Analyst sentiment remains mostly positive, with a consensus “Buy” rating and a $15.38 price target, despite Weiss Ratings maintaining a “sell” rating.
• Institutional ownership stands at 19.06%, highlighted by a significant increase in UBS Group’s holdings to 2.64 million shares. Inventiva’s lead drug candidate, lanifibranor, is in Phase III development for NASH.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report)'s stock price gapped down before the market opened on Friday . The stock had previously closed at $4.84, but opened at $4.63. Inventiva shares last traded at $4.65, with a volume of 161,983 shares.

Analysts Set New Price Targets

Several analysts have recently weighed in on IVA shares. Weiss Ratings restated a "sell (d-)" rating on shares of Inventiva in a report on Friday, July 17th. Cantor Fitzgerald began coverage on shares of Inventiva in a research report on Friday, July 17th. They issued an "overweight" rating on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $15.38.

Inventiva Price Performance

The company's 50 day simple moving average is $4.48 and its two-hundred day simple moving average is $5.03.

Institutional Trading of Inventiva

Several large investors have recently made changes to their positions in the stock. Creative Planning acquired a new position in shares of Inventiva during the 2nd quarter valued at about $32,000. Millennium Management LLC bought a new stake in Inventiva during the third quarter worth approximately $649,000. NewEdge Advisors LLC acquired a new position in Inventiva during the third quarter valued at approximately $116,000. UBS Group AG grew its holdings in Inventiva by 28,881.6% during the fourth quarter. UBS Group AG now owns 2,643,702 shares of the company's stock valued at $12,293,000 after purchasing an additional 2,634,580 shares during the last quarter. Finally, Simplify Asset Management Inc. bought a new position in shares of Inventiva in the fourth quarter valued at approximately $1,570,000. Institutional investors own 19.06% of the company's stock.

About Inventiva

Inventiva NASDAQ: IVA is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company's core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva's scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company's lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.